Cue Biopharma, Inc. (CUE)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Collaboration revenue | 2,954 | 421 | 3,336 | |
| Gain on fixed asset disposal | - | - | 97 | |
| Research and development | 7,910 | 8,547 | 9,381 | |
| General and administrative | 3,679 | 4,173 | 2,867 | |
| Total operating expenses | 11,589 | 12,720 | 12,151 | |
| Loss from operations | -8,635 | -12,299 | -8,815 | |
| Interest income | 198 | 170 | 343 | |
| Interest expense | -45 | -128 | -188 | |
| Total other income, net | 153 | 42 | 155 | |
| Net loss | -8,482 | -12,257 | -8,660 | |
| Comprehensive loss | -8,482 | -12,257 | -8,660 | |
| Net loss per common share, basic | -0.09 | -0.17 | -0.17 | |
| Net loss per common share, diluted | -0.09 | -0.17 | -0.17 | |
| Weighted average common shares outstanding, basic | 95,459,401 | 74,254,700 | 51,229,701 | |
| Weighted average common shares outstanding, diluted | 95,459,401 | 74,254,700 | 51,229,701 | |